Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × NPI 2358 × Clear all
NCT04902040 2026-04-30

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

M.D. Anderson Cancer Center

Phase 1/2 Terminated
19 enrolled 11 charts
GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT02846792 2019-03-04

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

University of Washington

Phase 1/2 Terminated
5 enrolled 8 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡